SI2116244T1 - Postopek za zdravljenje ateroskleroze, dislipidemij in povezanih stanj - Google Patents
Postopek za zdravljenje ateroskleroze, dislipidemij in povezanih stanjInfo
- Publication number
- SI2116244T1 SI2116244T1 SI200431951T SI200431951T SI2116244T1 SI 2116244 T1 SI2116244 T1 SI 2116244T1 SI 200431951 T SI200431951 T SI 200431951T SI 200431951 T SI200431951 T SI 200431951T SI 2116244 T1 SI2116244 T1 SI 2116244T1
- Authority
- SI
- Slovenia
- Prior art keywords
- dyslipidemias
- related conditions
- treating atherosclerosis
- atherosclerosis
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47066503P | 2003-05-15 | 2003-05-15 | |
EP09163448A EP2116244B1 (en) | 2003-05-15 | 2004-05-13 | Method of treating atherosclerosis, dyslipidemias and related conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2116244T1 true SI2116244T1 (sl) | 2012-12-31 |
Family
ID=33476734
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200431221T SI1624871T1 (sl) | 2003-05-15 | 2004-05-13 | Postopek za zdravljenje ateroskleroze, dislipidemije in sorodnih stanj in farmacevtski sestavki |
SI200431951T SI2116244T1 (sl) | 2003-05-15 | 2004-05-13 | Postopek za zdravljenje ateroskleroze, dislipidemij in povezanih stanj |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200431221T SI1624871T1 (sl) | 2003-05-15 | 2004-05-13 | Postopek za zdravljenje ateroskleroze, dislipidemije in sorodnih stanj in farmacevtski sestavki |
Country Status (45)
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094830A2 (en) * | 2001-05-23 | 2002-11-28 | Merck Frosst Canada & Co. | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS |
EP1603585A2 (en) * | 2003-03-14 | 2005-12-14 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
TWI258478B (en) | 2003-10-31 | 2006-07-21 | Arena Pharm Inc | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
US7019022B2 (en) * | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
ES2523796T1 (es) | 2004-10-08 | 2014-12-01 | Forward Pharma A/S | Composición farmacéutica de liberación controlada que comprende éster de ácido fumárico |
PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
US8165517B2 (en) * | 2005-01-19 | 2012-04-24 | The Trustees Of The University Of Pennsylvania | Methods for identifying inhibitors of vascular injury |
CA2598273A1 (en) * | 2005-02-17 | 2006-08-24 | Merck & Co., Inc. | Method of treating atherosclerosis, dyslipidemias and related conditions |
AU2006214286A1 (en) * | 2005-02-18 | 2006-08-24 | Arena Pharmaceuticals, Inc. | Methods and compositions for the treatment of lipid-associated disorders |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
EP1885726B1 (en) * | 2005-05-17 | 2016-12-14 | Merck Sharp & Dohme Corp. | Ortho-condensed 2-pyridinone derivatives as nicotinic acid receptor agonists for the treatment of dyslipidemia |
US7750015B2 (en) * | 2005-05-17 | 2010-07-06 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US20090258862A1 (en) * | 2005-08-29 | 2009-10-15 | Colletti Steven L | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
RU2008112313A (ru) * | 2005-09-01 | 2009-10-10 | Эррэй Биофарма Инк. (Us) | Соединения ингибиторы raf и способы их применения |
EP1940382A2 (en) * | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
CA2634940A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist |
JP2009521445A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | H3アンタゴニスト/逆アゴニストと食欲抑制剤との組み合わせ |
CA2637717A1 (en) * | 2006-01-20 | 2007-08-02 | Schering Corporation | Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia |
US20090069275A1 (en) * | 2006-02-17 | 2009-03-12 | Rocca Jose G | Low flush niacin formulation |
WO2008033464A2 (en) * | 2006-09-15 | 2008-03-20 | Schering Corporation | Azetidinone derivatives for the treatment of disorders of the lipid metabolism |
EP2091534A1 (en) * | 2006-09-15 | 2009-08-26 | Schering Corporation | Azetidinone derivatives and methods of use thereof |
CA2663434A1 (en) | 2006-09-15 | 2008-03-20 | Schering Corporation | Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders |
WO2008039882A1 (en) * | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
WO2008097535A2 (en) * | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Method of treating atherosclerosis, dyslipidemias and related conditions |
US20090076117A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched laropiprant |
CN101559058B (zh) * | 2008-04-16 | 2011-07-20 | 北京本草天源药物研究院 | 一种治疗血脂异常的药物组合物 |
RU2010151944A (ru) * | 2008-05-20 | 2012-06-27 | Серенис Терапьютикс С.А. (Fr) | Ниацин и нспвс для комбинированной терапии |
WO2010030360A1 (en) | 2008-09-11 | 2010-03-18 | Arena Pharmaceuticals, Inc. | 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS |
US20110165239A1 (en) * | 2008-09-24 | 2011-07-07 | Laman Alani | Pharmaceutical compositions of atorvastatin |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
DK2564839T3 (en) | 2009-01-09 | 2016-07-25 | Forward Pharma As | A pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
MX2012010038A (es) | 2010-03-16 | 2012-10-01 | Aventis Pharma Inc | Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2. |
EP2547672A1 (en) | 2010-03-16 | 2013-01-23 | Aventis Pharmaceuticals Inc. | Substituted pyrimidines as prostaglandin d2 receptor antagonists |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3535326A (en) * | 1967-03-06 | 1970-10-20 | Sumitomo Chemical Co | Certain tetrahydro carboline derivatives |
BE787444A (fr) * | 1971-08-13 | 1973-02-12 | Hoffmann La Roche | Composes polycycliques |
US4009181A (en) * | 1973-01-22 | 1977-02-22 | Hoffmann-La Roche Inc. | Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof |
US4057559A (en) * | 1973-10-01 | 1977-11-08 | American Home Products Corporation | Carbazole acetic acid derivatives |
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
JPS6352514B2 (sl) | 1977-09-30 | 1988-10-19 | Rca Corp | |
US4342767A (en) | 1980-01-23 | 1982-08-03 | Merck & Co., Inc. | Hypocholesteremic fermentation products |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US5021447A (en) * | 1986-01-23 | 1991-06-04 | Merck Frosst Canada, Inc. | Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions |
US4808608A (en) * | 1986-01-23 | 1989-02-28 | Merck & Co., Inc. | Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use |
US4940719A (en) * | 1986-03-27 | 1990-07-10 | Merck Frosst Canada, Inc. | Tetrahydrocarbazole esters, pharmaceutical compositions and use |
US4775680A (en) * | 1987-07-21 | 1988-10-04 | Merck & Co., Inc. | Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
US5190972A (en) * | 1992-01-27 | 1993-03-02 | The University Of Melbourne | Method of combatting cyclosporine organ toxicity with prostaglandin analogs |
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
EP0821587A4 (en) * | 1995-04-19 | 1999-05-19 | Lipoprotein Technologies Inc | COMPOSITIONS, KITS AND METHODS FOR ADMINISTERING ANTILIPEMICS AND MEDICINES AGAINST PLATELET AGGREGATION |
DK0877750T3 (da) | 1995-10-31 | 2002-07-15 | Schering Corp | Som hypocholesterolemiske midler velegnede, sukkersubstituerede 2-azetidinoner |
WO1997016424A1 (en) | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
CZ288545B6 (cs) | 1995-12-22 | 2001-07-11 | Kowa Company, Ltd. | Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové |
US5739321A (en) | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
US5886171A (en) | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
US20010006644A1 (en) * | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
US6469035B1 (en) * | 1997-07-31 | 2002-10-22 | Eugenio A. Cefali | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
PT1017390E (pt) * | 1997-07-31 | 2007-07-24 | Kos Life Sciences Inc | Comprimido revestido que compreende ácido nicotínico ou um composto metabolizado a ácido nicotínico sob uma forma de libertação prolongada, e um revestimento que contém um inibidor da hmg-coa-redutase sob uma forma de libertação imediata. |
RU2247722C2 (ru) * | 1997-10-27 | 2005-03-10 | Др. Редди`З Лабораториз Лимитед | Производные арилкарбоновых кислот, способы их получения, фармацевтическая композиция на их основе, способы лечения и предупреждения различных заболеваний, промежуточные соединения и способы их получения |
US6133001A (en) | 1998-02-23 | 2000-10-17 | Schering Corporation | Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone |
US5919672A (en) | 1998-10-02 | 1999-07-06 | Schering Corporation | Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone |
EP1137634B1 (en) | 1998-12-07 | 2005-06-15 | Schering Corporation | Process for the synthesis of azetidinones |
IL143944A0 (en) | 1998-12-23 | 2002-04-21 | Searle Llc | Combinations for cardiovascular indications |
CN1249250C (zh) | 1999-04-05 | 2006-04-05 | 先灵公司 | 用于制备1-(4-氟苯基)-3(R)-[3(S)-羟基-3-(4-氟苯基)丙基]-4(S)-(4-羟苯基)-2-β丙内酰胺的立体选择性微生物还原反应 |
AU4343500A (en) | 1999-04-16 | 2000-11-02 | Schering Corporation | Use of azetidinone compounds |
IT1306141B1 (it) * | 1999-05-17 | 2001-05-30 | Giampiero Valletta | Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche. |
CN1179945C (zh) | 2000-03-09 | 2004-12-15 | 小野药品工业株式会社 | 吲哚衍生物、其制备方法及用途 |
US20010047027A1 (en) * | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
JP2002008186A (ja) * | 2000-06-23 | 2002-01-11 | Mitsubishi Heavy Ind Ltd | 車種識別装置 |
US6410583B1 (en) * | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
JP3889563B2 (ja) * | 2000-09-13 | 2007-03-07 | 三洋電機株式会社 | 映像信号処理回路 |
EP1377834A2 (en) | 2001-04-11 | 2004-01-07 | Glaxo Group Limited | Medicaments which are modulators of hm74 and/or hm74a activity |
WO2002094830A2 (en) | 2001-05-23 | 2002-11-28 | Merck Frosst Canada & Co. | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS |
EP1424335A4 (en) | 2001-09-07 | 2005-11-16 | Ono Pharmaceutical Co | INDOLE DERIVATIVES |
AR038136A1 (es) * | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
BR0308518A (pt) | 2002-03-19 | 2005-02-22 | Ono Pharmaceutical Co | Compostos ácidos carboxìlicos e drogas contendo os compostos como o ingrediente ativo |
EP1513519B1 (en) * | 2002-06-03 | 2009-02-18 | Novartis AG | The use of substituted cyanopyrrolidines for treating hyperlipidemia |
US7019022B2 (en) * | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
JP4129960B2 (ja) * | 2005-07-01 | 2008-08-06 | タキゲン製造株式会社 | ステー |
-
2004
- 2004-05-05 AR ARP040101527A patent/AR041089A1/es unknown
- 2004-05-06 JO JO200454A patent/JO2564B1/en active
- 2004-05-06 PE PE2004000463A patent/PE20050552A1/es not_active Application Discontinuation
- 2004-05-10 MY MYPI20041729A patent/MY140639A/en unknown
- 2004-05-13 ES ES04785539T patent/ES2328148T3/es not_active Expired - Lifetime
- 2004-05-13 PT PT09163448T patent/PT2116244E/pt unknown
- 2004-05-13 RS YU20050777A patent/RS52731B/sr unknown
- 2004-05-13 DK DK09163448.5T patent/DK2116244T3/da active
- 2004-05-13 JP JP2006515355A patent/JP4637833B2/ja not_active Expired - Fee Related
- 2004-05-13 KR KR1020057021795A patent/KR100806008B1/ko active IP Right Grant
- 2004-05-13 GE GEAP200410277A patent/GEP20105025B/en unknown
- 2004-05-13 GE GEAP20049114A patent/GEP20084569B/en unknown
- 2004-05-13 NZ NZ543399A patent/NZ543399A/en not_active IP Right Cessation
- 2004-05-13 BR BRPI0410273-8A patent/BRPI0410273A/pt not_active IP Right Cessation
- 2004-05-13 WO PCT/US2004/014980 patent/WO2004103370A1/en active Application Filing
- 2004-05-13 DE DE602004022036T patent/DE602004022036D1/de not_active Expired - Lifetime
- 2004-05-13 AU AU2004240597A patent/AU2004240597B2/en not_active Ceased
- 2004-05-13 SI SI200431221T patent/SI1624871T1/sl unknown
- 2004-05-13 ES ES09163448T patent/ES2392743T3/es not_active Expired - Lifetime
- 2004-05-13 PT PT04785539T patent/PT1624871E/pt unknown
- 2004-05-13 CN CNB2004800128531A patent/CN100441184C/zh not_active Expired - Fee Related
- 2004-05-13 NZ NZ572515A patent/NZ572515A/en not_active IP Right Cessation
- 2004-05-13 EA EA200501817A patent/EA009744B1/ru not_active IP Right Cessation
- 2004-05-13 ME MEP-601/08A patent/MEP60108A/xx unknown
- 2004-05-13 MX MXPA05012272A patent/MXPA05012272A/es active IP Right Grant
- 2004-05-13 PL PL09163448T patent/PL2116244T3/pl unknown
- 2004-05-13 EP EP09163448A patent/EP2116244B1/en not_active Expired - Lifetime
- 2004-05-13 KR KR1020077029888A patent/KR100960749B1/ko not_active IP Right Cessation
- 2004-05-13 SG SG200708456-9A patent/SG153667A1/en unknown
- 2004-05-13 PL PL04785539T patent/PL1624871T3/pl unknown
- 2004-05-13 US US10/844,773 patent/US20040229844A1/en not_active Abandoned
- 2004-05-13 DK DK04785539T patent/DK1624871T3/da active
- 2004-05-13 EA EA200702674A patent/EA011895B1/ru not_active IP Right Cessation
- 2004-05-13 RS RS20120499A patent/RS20120499A1/en unknown
- 2004-05-13 EP EP04785539A patent/EP1624871B1/en not_active Expired - Lifetime
- 2004-05-13 RS RS20120498A patent/RS20120498A1/en unknown
- 2004-05-13 SI SI200431951T patent/SI2116244T1/sl unknown
- 2004-05-13 CN CN2012100149106A patent/CN102526735A/zh active Pending
- 2004-05-13 CN CN2008101690579A patent/CN101559227B/zh not_active Expired - Fee Related
- 2004-05-13 GT GT200400098A patent/GT200400098A/es unknown
- 2004-05-13 UA UAA200512018A patent/UA89615C2/ru unknown
- 2004-05-13 CA CA2525772A patent/CA2525772C/en not_active Expired - Fee Related
- 2004-05-13 EP EP10182413A patent/EP2286816A1/en not_active Withdrawn
- 2004-05-14 HN HN2004000171A patent/HN2004000171A/es unknown
- 2004-05-14 DO DO2004000907A patent/DOP2004000907A/es unknown
- 2004-05-14 TW TW096125297A patent/TWI341199B/zh not_active IP Right Cessation
- 2004-05-14 CL CL200401056A patent/CL2004001056A1/es unknown
- 2004-05-14 PA PA20048603201A patent/PA8603201A1/es unknown
- 2004-05-14 TW TW093113730A patent/TWI334354B/zh not_active IP Right Cessation
-
2005
- 2005-10-13 ZA ZA200508288A patent/ZA200508288B/xx unknown
- 2005-10-13 IS IS8071A patent/IS2708B/is unknown
- 2005-10-19 CR CR8047A patent/CR8047A/es unknown
- 2005-11-09 MA MA28589A patent/MA27835A1/fr unknown
- 2005-11-10 CO CO05114676A patent/CO5630034A2/es active IP Right Grant
- 2005-11-11 EC EC2005006156A patent/ECSP056156A/es unknown
- 2005-11-14 TN TNP2005000290A patent/TNSN05290A1/en unknown
- 2005-11-14 IL IL171962A patent/IL171962A/en not_active IP Right Cessation
- 2005-12-14 NO NO20055957A patent/NO20055957L/no not_active Application Discontinuation
-
2006
- 2006-12-11 HK HK06113584.9A patent/HK1092722A1/xx not_active IP Right Cessation
-
2008
- 2008-03-11 CR CR9808A patent/CR9808A/es not_active Application Discontinuation
-
2009
- 2009-05-21 US US12/470,049 patent/US20090233977A1/en not_active Abandoned
- 2009-07-31 HR HR20090424T patent/HRP20090424T1/xx unknown
- 2009-10-13 CY CY20091101051T patent/CY1109476T1/el unknown
- 2009-11-30 US US12/627,787 patent/US20100076002A1/en not_active Abandoned
- 2009-12-02 JP JP2009274146A patent/JP2010077151A/ja active Pending
-
2011
- 2011-01-24 US US13/012,696 patent/US20110118292A1/en not_active Abandoned
- 2011-03-07 AU AU2011200986A patent/AU2011200986B2/en not_active Ceased
-
2012
- 2012-10-11 HR HRP20120818TT patent/HRP20120818T1/hr unknown
- 2012-11-05 CY CY20121101050T patent/CY1113342T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2116244T3 (pl) | Sposób leczenia miażdżycy naczyń, dyslipidemii i związanych z nimi dolegliwości | |
EP1855649A4 (en) | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIA AND BINDING DISORDERS | |
HK1077041A1 (en) | Conduit and method of forming | |
GB2398810B (en) | Well treatment method and system | |
AU2003283958A8 (en) | Method of treating tremors | |
ZA200600593B (en) | Press-hardened component and associated production method | |
IL175351A0 (en) | Methods of treating asthma | |
IL164219A0 (en) | Method for treating and preventing hyparathyroidism | |
IL166600A0 (en) | Method of treating osteoarthritis | |
AU2003262946A1 (en) | Method of preventing or treating atherosclerosis or restenosis | |
GB0323068D0 (en) | Dewatering treatment system and method | |
ZA200108494B (en) | Method of treating cartilage damage. | |
EP1575567A4 (en) | METHOD AND REAGENTS FOR TREATING OR PREVENTING ATHEROSCLEROSIS AND DISEASES ASSOCIATED WITH IT | |
GB0311953D0 (en) | Plant treatment method and means therefor | |
GB0306309D0 (en) | Method of treatment | |
ZA200303274B (en) | Method of treating shellfish. | |
GB0302572D0 (en) | Method of treatment | |
GB2420947A8 (en) | Communications apparatus and method | |
AU2003262910A1 (en) | Method of preventing or treating atherosclerosis or restenosis | |
AU2003290612A8 (en) | Apparatus and method for treating strial hearing loss | |
EP1604748A4 (en) | METHOD FOR THE TREATMENT OF WASTE GLASS | |
EP1688503A4 (en) | METHOD FOR THE TREATMENT OF CELLS | |
ZA200606071B (en) | Methods of treating asthma | |
GB0422041D0 (en) | Well treatment system and method | |
GB0302839D0 (en) | Communications apparatus and method |